Results 51 to 60 of about 2,108 (191)

Faricimab at 6 and 12 mg reduces pigment epithelium detachment in treatment-resistant macular neovascularization: an OCT and AI analysis

Scientific Reports
Macular neovascularization (MNV) in age-related macular degeneration (AMD) remains a therapeutic challenge, especially in eyes resistant to conventional anti-VEGF therapy.
Ines D. Nagel, Melanie D. Tran, Haochen Zhang, Lingyun Cheng, Anna Heinke, Nehal N. Mehta, Dirk-Uwe Bartsch, Fritz G. P. Kalaw, Mohamed Morsy, Arthur J. Mueller, William R. Freeman   +10 more
doaj   +1 more source

Faricimab for Treatment-Resistant Diabetic Macular Edema

Clinical Ophthalmology, 2022
To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF).A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts.
Ryan B Rush, Sloan W Rush
openaire   +3 more sources

Recent Investigations on Pathogenesis, Biomarkers, Epigenetics, and Emerging Therapeutic Strategies to Modulate Multiple Signaling Pathways in Diabetic Retinopathy

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative ...
Zixuan Huang, Jing Wei, Dayong Yang, Kofi Asiedu   +3 more
wiley   +1 more source

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept [PDF]

We investigated the factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA).
Hirata, Yuki, Ikeda, Junichiro, Kitaoka, Takashi, Kurihara, Junko, Machida, Akira, Murakami, Ryuya, Oishi, Akio, Tsuiki, Eiko, Yoneda, Ai   +8 more
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

International Journal of Retina and Vitreous
Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab ...
Fernando M Penha, Maliha Masud, Zoha A. Khanani, Mathew Thomas, Rodney D. Fong, Kyler Smith, Avishay Chand, Majid Khan, Greggory Gahn, Gustavo Barreto Melo, Arshad M. Khanani   +10 more
doaj   +1 more source

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1156-1167, December 2025.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies   +9 more
wiley   +1 more source

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials [PDF]

Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with ...
, Asik Kemal, Baumal Caroline R., Csaky Karl G., Eter Nicole, Haskova Zdenka, Hee Yoon Young, Ives Jane A., Jaffe Glenn J., Kollaborációs szervezet: YOSEMITE and RHINE Investigators, Korobelnik Jean-François, Lin Hugh, Murata Toshinori, Papp András, Ruamviboonsuk Paisan, Schlottmann Patricio G., Seres András I., Silverman David, Sun Xiaodong, Tang Yannan, Tóth-Molnár Edit, Wells John A., Wong Tien Y., Wykoff Charles C.   +23 more
core   +1 more source